Int J Impot Res:勃起和射精功能障碍糖尿病患者低剂量和高剂量他达拉非药物使用对比研究

2018-05-31 AlexYang MedSci原创

最近,有研究人员比较了每日5mg和按需使用20mg他达拉非药物在具有勃起功能障碍(ED)糖尿病患者中使用情况,以及2中不同的用药剂量方式对射精和下尿道症状(LUTS)影响。研究包括了63名患有ED的糖尿病患者,其中31名每天使用5mg他达拉非,32名按需每个月进行4次的使用,每次20mg,共进行3个月。勃起功能、勃起硬度、射精功能和LUTS在治疗前、治疗第一个月和第三个月时进行评估。研究发现,2种

最近,有研究人员比较了每日5mg和按需使用20mg他达拉非药物在具有勃起功能障碍(ED)糖尿病患者中使用情况,以及2中不同的用药剂量方式对射精和下尿道症状(LUTS)影响。

研究包括了63名患有ED的糖尿病患者,其中31名每天使用5mg他达拉非,32名按需每个月进行4次的使用,每次20mg,共进行3个月。勃起功能、勃起硬度、射精功能和LUTS在治疗前、治疗第一个月和第三个月时进行评估。研究发现,2种他达拉非药物使用方法在年龄小于65岁的所有患者中均增加了国际勃起功能(IIEF)得分。然而年龄大于65岁的患者并没有改善。射精功能、勃起硬度质量和LUTS在2个小组中均得到了改善。

最后,研究人员指出,他达拉非能够改善患有ED的糖尿病男性的性功能,并且副作用可以接受。2中使用方法都能均等的改善LUTS和勃起的质量。日常使用5mg他达拉非能够显著改善射精质量和LUTS,且比20mg每次用量效果更好。另外,5mg每天的用量对年龄大于65岁的或者患有LUTS且年龄大于65岁的患者效果可能更好。

原始出处:

Mustafa Suat Bolat, Onder Cinar, Ekrem Akdeniz et al. Low dose daily versus on-demand high dose tadalafil in diabetic patients with erectile and ejaculatory dysfunction. Int J Impot Res. 25 May 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2019-03-17 habb
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-06-02 风铃826
  10. [GetPortalCommentsPageByObjectIdResponse(id=1771149, encodeId=e1261e71149f5, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Sun Mar 17 08:43:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971563, encodeId=1f8019e15637e, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Tue Nov 20 22:43:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942093, encodeId=4c44194209362, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Oct 09 23:43:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421162, encodeId=bb1c14211629e, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440087, encodeId=5050144008e24, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457777, encodeId=2954145e777bc, content=<a href='/topic/show?id=68a62535962' target=_blank style='color:#2F92EE;'>#他达拉非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25359, encryptionId=68a62535962, topicName=他达拉非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d26b5981715, createdName=yangshch, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474511, encodeId=c7f714e45110b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480498, encodeId=d56114804980c, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575079, encodeId=bf5915e5079d6, content=<a href='/topic/show?id=6f66121e89e' target=_blank style='color:#2F92EE;'>#MPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12178, encryptionId=6f66121e89e, topicName=MPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b9016060451, createdName=风铃826, createdTime=Sat Jun 02 09:43:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320318, encodeId=23f0320318a2, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 31 19:53:25 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 131****1460

    学习了受益匪浅

    0

相关资讯

JAMA:他达拉非不改善前列腺癌放疗后勃起功能障碍

根据在线发表于2014年4月2日《美国医学会杂志》上的一则研究报道,在因为前列腺癌而接受了放疗的男性患者人群中,与安慰剂相比,每日使用勃起障碍治疗药物他达拉非(tadalafil)并未阻止勃起功能的丧失。他达拉非被用于前列腺癌治疗后的勃起功能障碍,但其作为一种预防性药物的作用还没有得到确定。勃起功能障碍(ED)是一种可由许多原因引起的常见病,这些原因中包括对前列腺癌的治疗。据估计,在接受放疗后,有

Clin Cancer Res:他达拉非能增加头颈部鳞癌患者的肿瘤特性免疫

目的:明确磷酸二酯酶5(PDE5)能否通过阻断髓源性抑制细胞(MDSC)进而增加头颈部肿瘤患者的免疫功能。 试验设计:我们做了一个随机的、前瞻性的、双盲的、有安慰剂对照的II期临床试验,用以明确PDE5抑制剂对于头颈部鳞癌患者免疫功能的作用。 结果:他达拉非增加了患者的免疫反应。相对于对照组的1.1倍,他达拉非组使患者体内T细胞扩增了2.4倍(P=0.01)。同时他达拉非使患者体内的外周MDS

NEJM:安贝生坦和他达拉非初始联合治疗肺动脉高压已见成效

使用安贝生坦和他达拉非初始联合治疗肺动脉高压患者长期预后的的效果数据少之又少。在这项事件驱动的、双盲研究中,研究人员随机以2:1:1的比例分配世界卫生组织功能II级或III症状的肺动脉高压且以前没有接受过治疗的患者接受初步联合治疗,即10毫克安贝生坦加40毫克他达拉非(联合治疗组),或10毫克安贝生坦+安慰剂(安贝生坦单药治疗组),或40毫克他达拉非加安慰剂(他达那非单药治疗组),全部给予每日一次

ERS 2014:AMBITION试验揭示肺动脉高压新治疗方法

2014年欧洲呼吸年会上发布的AMBITION试验结果显示,联用安立生坦与他达拉非治疗肺动脉高压,较分别单用两药可显著降低住院率。 “我们的研究是首例比较不同治疗策略的随机对照试验,结果发现,联用安立生坦与他达拉非治疗肺动脉高压较分别单用两药临床效果更好,主要体现在降低住院率上(表)。就效价比而言,虽然联用药物会增加费用,但毕竟住院费用也较高。”研究者介绍说。 表AMBITION试

SCI TRANSL MED:进行性肌营养不良药物研究取得进展

       最近一项研究显示用于治疗勃起功能障碍和肺动脉高压的药物他达拉非还可纠正Becker型肌营养不良症(BMD)男性前臂活动时血流异常。发表在11月28日《科学转化医学》杂志的一项概念验证试点研究显示,他达拉非治疗可缓解功能性肌肉缺血,使一小部分BMD男性肌肉血流量恢复正常。        研究者称,“